Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay
about
Comprehensive analysis of interactions between the Src-associated protein in mitosis of 68 kDa and the human Src-homology 3 proteomeHost-pathogen interactome mapping for HTLV-1 and -2 retrovirusesHuman immunodeficiency virus 1 envelope-initiated G2-phase programmed cell deathInhibitory effect of 2',3'-didehydro-2',3'-dideoxynucleosides on infectivity, cytopathic effects, and replication of human immunodeficiency virusPathogenesis of human immunodeficiency virus infectionEnvelope glycoprotein and CD4 independence of vpu-facilitated human immunodeficiency virus type 1 capsid exportDiscovery of small-molecule HIV-1 fusion and integrase inhibitors oleuropein and hydroxytyrosol: Part I. fusion [corrected] inhibitionMechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitroCellulose acetate phthalate, a common pharmaceutical excipient, inactivates HIV-1 and blocks the coreceptor binding site on the virus envelope glycoprotein gp120Interaction of silver nanoparticles with HIV-1.Impact of TRIM5α in vivoRetroviral coinfections: HIV and HTLV: taking stock of more than a quarter century of researchThe broad anti-viral agent glycyrrhizin directly modulates the fluidity of plasma membrane and HIV-1 envelopeHIV Cell-to-Cell Spread Results in Earlier Onset of Viral Gene Expression by Multiple Infections per CellAnti-human immunodeficiency virus activity of a novel synthetic peptide, T22 ([Tyr-5,12, Lys-7]polyphemusin II): a possible inhibitor of virus-cell fusionPotent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating eventInhibition of human immunodeficiency virus (HIV) infection in vitro by anticarbohydrate monoclonal antibodies: peripheral glycosylation of HIV envelope glycoprotein gp120 may be a target for virus neutralizationIntracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a potent anti-human immunodeficiency virus compoundIn vitro anti-human immunodeficiency virus type 1 activity of biliverdin, a bile pigmentZidovudine-resistant human immunodeficiency virus selected by passage in cell cultureApolipoprotein A-I and its amphipathic helix peptide analogues inhibit human immunodeficiency virus-induced syncytium formationAn inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infectionLipophilic halogenated congeners of 2',3'-dideoxypurine nucleosides active against human immunodeficiency virus in vitroAnti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitorsEvaluation of an antimicrobial soap formula for virucidal efficacy in vitro against human immunodeficiency virus in a blood-virus mixtureInhibition of infectivity of human immunodeficiency virus by a novel nucleoside, oxetanocin, and related compoundsAmino acid deletion at codon 67 and Thr-to-Gly change at codon 69 of human immunodeficiency virus type 1 reverse transcriptase confer novel drug resistance profilesRibavirin antagonizes inhibitory effects of pyrimidine 2',3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides on replication of human immunodeficiency virus in vitroDideoxynucleosides are less inhibitory in vitro against human immunodeficiency virus type 2 (HIV-2) than against HIV-1High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptaseViral resistance to the thiazolo-iso-indolinones, a new class of nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptaseNovel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'-dideoxythymidine in cell cultureThe PETT series, a new class of potent nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptasePhotodynamic inactivation of infectivity of human immunodeficiency virus and other enveloped viruses using hypericin and rose bengal: inhibition of fusion and syncytia formationRapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptaseU-90152, a potent inhibitor of human immunodeficiency virus type 1 replicationpol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivoInhibition of human immunodeficiency virus type 1 infection and syncytium formation in human cells by V3 loop synthetic peptides from gp120SPC3, a synthetic peptide derived from the V3 domain of human immunodeficiency virus type 1 (HIV-1) gp120, inhibits HIV-1 entry into CD4+ and CD4- cells by two distinct mechanisms
P2860
Q21134534-6604CAF1-665E-433C-84AC-B9C12646EB1CQ21245042-0ADBB221-FBE9-4BEE-B27C-F10ECBB9939EQ24564325-26007B41-CDF1-4861-A005-B2E09F8F8AFBQ24619823-B4FB2551-59D7-42E7-A26C-7BD6750DD315Q24634681-713655FF-F4B5-4BCD-B2CD-BCDC30354753Q24644301-4D3FA15C-5BB7-409E-8B93-56E20315B1CCQ24644512-24AC62CE-9D9D-4DA0-B458-AD8C117F9DF8Q24650946-21415982-689E-45C5-A519-C162A6744F94Q24806134-A206F41E-9417-4931-83C2-B65085D829EEQ24815783-F23336DA-C1FF-40F5-AD3B-E55B5204A35CQ26786870-6278539D-2E67-484F-9DCF-EDE9492219C3Q26853678-DD8BBA65-5E41-4B02-9459-A452A59169E0Q27472782-B8731461-7FE3-4244-AC5A-AF03FBB2B543Q27681313-36368080-5B92-498A-B3C3-6977BC5AFE27Q28316430-C14A6E78-E908-4E81-AD5F-593C1BAD53F6Q28320362-3787A541-DF4B-408D-A750-1772E80E10D7Q28323332-140547CC-33C8-4FF0-9647-330596A73881Q28323687-6334E81C-5D73-48DB-856A-408EEA99EE5EQ28324023-5E0A351C-A602-45F4-8D4A-FC23EB8E9544Q28324074-A255EB37-D721-4096-AACE-2497C8277E7AQ28330684-809A5185-A396-4078-A01D-B474B22E355DQ28331494-244F53B9-457B-4D71-B967-D1FAB7500639Q28332188-690CB69A-2FE6-434E-B24C-9F3807D7ECAFQ28333679-3D94B158-3B45-4156-886D-62B4155772A7Q28342745-8BCF8ADD-C464-469E-8BE5-C883475DD37FQ28354384-B10234BE-88E7-4A0A-856F-B9FF4767F7E3Q28359652-D06D423E-58ED-4986-8E2A-92647AC12E2AQ28361269-A3D1F516-A071-497F-95EB-C4F064078558Q28361577-ECB42317-B204-4B14-9250-F397912C30BBQ28361679-041B1473-9BED-4C2A-AB2C-76CFDE6E2E05Q28367493-7FBE2902-554D-42D9-9AE2-B3F6323233C4Q28367531-B39C57C9-488F-4F29-B115-6D0A5ED5308BQ28367594-DA99269C-4C71-4110-815C-6B2EED447C23Q28367759-7EDA3768-7387-4551-9DA8-6FCBA14F6541Q28367994-6B999257-F583-400B-ABFF-C6EFAECCCA89Q28368030-6748F6BA-E998-47D1-8F7E-33D5BBD28134Q28368034-18457086-EDD4-44CF-AB56-4DEDDA0A19B9Q28368048-6A264909-42F0-49BA-8312-735DD955D4BDQ28368050-C9AFB05B-F8CC-42CE-9D6A-A5D951D706EAQ28368122-717456E0-1039-4ED6-BD23-7F07DC11B494
P2860
Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay
description
1985 nî lūn-bûn
@nan
1985 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1985 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1985年の論文
@ja
1985年論文
@yue
1985年論文
@zh-hant
1985年論文
@zh-hk
1985年論文
@zh-mo
1985年論文
@zh-tw
1985年论文
@wuu
name
Infection of HTLV-III/LAV in H ...... application in a plaque assay
@ast
Infection of HTLV-III/LAV in H ...... application in a plaque assay
@en
type
label
Infection of HTLV-III/LAV in H ...... application in a plaque assay
@ast
Infection of HTLV-III/LAV in H ...... application in a plaque assay
@en
prefLabel
Infection of HTLV-III/LAV in H ...... application in a plaque assay
@ast
Infection of HTLV-III/LAV in H ...... application in a plaque assay
@en
P2093
P3181
P356
P1433
P1476
Infection of HTLV-III/LAV in H ...... application in a plaque assay
@en
P2093
P3181
P356
10.1126/SCIENCE.2992081
P407
P577
1985-08-09T00:00:00Z